First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
NCT07332455
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Neoplasms, Prostate
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- September 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- GSK Investigational Site · La Jolla, CA
Michigan · 1
- GSK Investigational Site · Grand Rapids, MI
Pennsylvania · 1
- GSK Investigational Site · Philadelphia, PA
Utah · 1
- GSK Investigational Site · West Valley City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.